The 2020 Interstitial Cystitis (Painful Bladder Syndrome) pipeline report presents a comprehensive overview of the research and development of Interstitial Cystitis (Painful Bladder Syndrome) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: One drug in Research phase, six drugs in Pre-clinical phase, five drugs in Phase 2, and two drugs in Phase 3.
As of February 2020, the Interstitial Cystitis (Painful Bladder Syndrome) pipeline remains robust with 15 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Interstitial Cystitis (Painful Bladder Syndrome) treatment. Diverse types of targeted therapies are being explored through clinical trials including Cell membrane permeability inhibitors; Mitogen-activated protein kinase 8 inhibitors; Nociceptin receptor agonists; PAR-1 antagonist; Purinergic P2X3 receptor antagonists; SNAP-25 inhibitor; Sodium channel antagonists; Thrombin inhibitors; Tumor Necrosis Factor Alpha (TNF-a) Inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Interstitial Cystitis (Painful Bladder Syndrome) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
Publisher Expertise
The publisher's online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
Scope:
Interstitial Cystitis (Painful Bladder Syndrome) pipeline companies included in the report are: Alivio Therapeutics Inc, BELLUS Health Inc, GlycoMira Therapeutics Inc, Grunenthal GmbH, Harrow Health Inc, Kyorin Pharmaceutical Co Ltd, Lipella Pharmaceuticals Inc, Pierre Fabre Pharmaceuticals Inc, Seikagaku Corporation, UCB SA, Urigen Pharmaceuticals Inc, Xigen SA.
Interstitial Cystitis (Painful Bladder Syndrome) pipeline drugs profiled in the report include: ALV-107, GM-0111, GRT6010, 32264, KRP-116D (dimethyl sulfoxide), LP-08, Botulinum toxin A , BLU-5937 (NEO-5937), F 16357, certolizumab pegol, URG101 (heparin and lidocaine), URG501 (pentosan polysulfate), URG 801, XG-102 (brimapitide), SI-722.
As of February 2020, the Interstitial Cystitis (Painful Bladder Syndrome) pipeline remains robust with 15 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Interstitial Cystitis (Painful Bladder Syndrome) treatment. Diverse types of targeted therapies are being explored through clinical trials including Cell membrane permeability inhibitors; Mitogen-activated protein kinase 8 inhibitors; Nociceptin receptor agonists; PAR-1 antagonist; Purinergic P2X3 receptor antagonists; SNAP-25 inhibitor; Sodium channel antagonists; Thrombin inhibitors; Tumor Necrosis Factor Alpha (TNF-a) Inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Interstitial Cystitis (Painful Bladder Syndrome) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
Publisher Expertise
The publisher's online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
Scope:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Interstitial Cystitis (Painful Bladder Syndrome) development
- Interstitial Cystitis (Painful Bladder Syndrome) pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Interstitial Cystitis (Painful Bladder Syndrome) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Interstitial Cystitis (Painful Bladder Syndrome) pipeline candidates included
- Business overview and snapshot of all companies involved in Interstitial Cystitis (Painful Bladder Syndrome) pipeline are included
- Latest market and pipeline developments are provided in the report
Interstitial Cystitis (Painful Bladder Syndrome) pipeline companies included in the report are: Alivio Therapeutics Inc, BELLUS Health Inc, GlycoMira Therapeutics Inc, Grunenthal GmbH, Harrow Health Inc, Kyorin Pharmaceutical Co Ltd, Lipella Pharmaceuticals Inc, Pierre Fabre Pharmaceuticals Inc, Seikagaku Corporation, UCB SA, Urigen Pharmaceuticals Inc, Xigen SA.
Interstitial Cystitis (Painful Bladder Syndrome) pipeline drugs profiled in the report include: ALV-107, GM-0111, GRT6010, 32264, KRP-116D (dimethyl sulfoxide), LP-08, Botulinum toxin A , BLU-5937 (NEO-5937), F 16357, certolizumab pegol, URG101 (heparin and lidocaine), URG501 (pentosan polysulfate), URG 801, XG-102 (brimapitide), SI-722.
Table of Contents
1. Table of Contents
2. Executive Summary
3. Companies Active in Pipeline Development
4. Active Pipeline Drug Details, 2020
6. Appendix
Companies Mentioned
- Alivio Therapeutics Inc
- BELLUS Health Inc
- GlycoMira Therapeutics Inc
- Grunenthal GmbH
- Harrow Health Inc
- Kyorin Pharmaceutical Co Ltd
- Lipella Pharmaceuticals Inc
- Pierre Fabre Pharmaceuticals Inc
- Seikagaku Corporation
- UCB SA
- Urigen Pharmaceuticals Inc
- Xigen SA
